Luminex, One Lambda Renew Alliance | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex said after the close of the market Tuesday that it has renewed its 10-year strategic partnership with One Lambda.

The alliance, which began in 2000, is focused on developing platforms and technologies for human leukocyte antigen typing and antibody screening for the organ transplantation market. One Lamda has developed a range of HLA tests based on Luminex's xMAP technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.